Eosinophilic Esophagitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Eosinophilic Esophagitis - Pipeline Review, H1 2016', provides an overview of the Eosinophilic Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis - The report reviews pipeline therapeutics for Eosinophilic Esophagitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Eosinophilic Esophagitis therapeutics and enlists all their major and minor projects - The report assesses Eosinophilic Esophagitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Eosinophilic Esophagitis Overview 6 Therapeutics Development 7 Pipeline Products for Eosinophilic Esophagitis - Overview 7 Eosinophilic Esophagitis - Therapeutics under Development by Companies 8 Eosinophilic Esophagitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Eosinophilic Esophagitis - Products under Development by Companies 12 Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 13 Celgene Corporation 13 DBV Technologies S.A. 14 Dr. Falk Pharma GmbH 15 Novartis AG 16 Regeneron Pharmaceuticals, Inc. 17 Shire Plc 18 Eosinophilic Esophagitis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Allergen for Milk Allergy - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 budesonide - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 budesonide - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 dectrekumab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 dupilumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 fluticasone propionate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Qi-406 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 RPC-4046 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Eosinophilic Esophagitis - Recent Pipeline Updates 43 Eosinophilic Esophagitis - Dormant Projects 52 Eosinophilic Esophagitis - Product Development Milestones 53 Featured News & Press Releases 53 Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 53 Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 53 Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 54 Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 54 Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 55 May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 56 Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 57 May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 57 May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Eosinophilic Esophagitis - Pipeline by Celgene Corporation, H1 2016 13 Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H1 2016 14 Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 15 Eosinophilic Esophagitis - Pipeline by Novartis AG, H1 2016 16 Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 17 Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H1 2016 43 Eosinophilic Esophagitis - Dormant Projects, H1 2016 52
List of Figures
Number of Products under Development for Eosinophilic Esophagitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmenRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.